Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email

Cancer Immune Monitoring and Analysis Centers (CIMACs) and Cancer Immunologic Data Center (CIDC) Network

Established in 2017, the CIMACs-CIDC Network collaborates with clinical trial investigators to design and perform biomarker and correlative studies in clinical trials of cancer immunotherapy.

Network Purpose

The network’s purpose is to provide comprehensive immune profiling of clinical trial specimens to identify biomarkers for improving immunotherapy, including improved selection of cancer patients for immunotherapy.

The CIMACs-CIDC Network, which is supported by multiple cooperative agreements, provides multimodal assays and correlative analysis to identify biomarkers of response, resistance, and toxicity to cancer immunotherapy. It aims to understand the mechanisms underlying these processes.

CIMACs work with clinical trial investigators on correlative studies across multiple cancer trials of immunotherapy. They use a range of harmonized and validated state-of-the-art assays, spanning genomics, proteomics, transcriptomics, immune phenotyping, functional analyses, and epigenetics.

Correlative study teams comprising CIMACs and clinical trial investigators send biomarker and clinical data, respectively, from the trials to a central database (CIDC). The teams then work with these data on both trial-specific and cross-trial analyses for biomarker discovery. Data from this centralized immuno-oncology (IO) database are also shared with the research community through the NCI Cancer Research Data Commons (CRDC), with requests for data submitted to dbGaP.

Using the approaches listed below, the network addresses several challenges in IO cancer biomarker research, including the complexity of the tumor-immune interface, heterogeneity of methods and specimens across studies, and small trial sizes:

ChallengeApproach
Complex interplay between cancer and immune systemComprehensive specimen profiling of tumor, tumor microenvironment, blood, and other specimens
Variability in assay performance among labs

Harmonized and standardized state-of-the-art, multimodal assays

Centralized bioinformatics pipelines

Tumor and interpatient heterogeneityStandardized clinical data, specimens, and assays to enable cross-trial analysis
Small size of patient cohorts in clinical trials

Larger sample sizes through cross-trial analysis

Central database of biomarker and clinical data from multiple trials

Network Structure

An overview of the CIMACs-CIDC Network is published in Clinical Cancer Research.

CIMACs

The following four CIMACs are academic laboratories at leading cancer research institutions that perform multi-modal assay analysis using specimens from immunotherapy clinical trials:

  1. Dana-Farber Cancer Institute
  2. Icahn School of Medicine at Mount Sinai
  3. MD Anderson Cancer Center
  4. Stanford University

CIDC

NCI operates the data center, which collects clinical and biomarker data from the immunotherapy trials collaborating with CIMACs. CIDC performs the following:

  • Distributes data to authorized researchers in the network.
  • Standardizes assay data across trials using centralized bioinformatics pipelines.
  • Intakes a standardized set of clinical data elements across trials.
  • Facilitates cross-trial analysis of correlative data.
  • Maintains and operates the growing central immuno-oncology database.
  • Sends data to the CRDC for sharing with the general research community.

Clinical Sample Management System (CSMS)

  • Tracks and manages specimens among the many network sites.

The Partnership for Accelerating Cancer Therapies (PACT)

  • Provides significant financial and scientific support to the network, including additional clinical trials for collaboration.
  • A public-private research collaboration among NIH, FNIH, FDA, and 12 leading pharmaceutical companies.

Learn more about the FNIH PACT.

Principal Investigators

Dana-Farber Cancer Institute

Catherine J. Wu, M.D. 
Chief, Division of Stem Cell Transplantation and Cellular Therapies
Professor of Medicine, Harvard Medical School

Stephen Hodi, M.D.
Director, Melanoma Center and Center for Immuno-Oncology
Professor of Medicine, Harvard Medical School

Icahn School of Medicine at Mount Sinai

Sacha Gnjatic, Ph.D.
Associate Director, Human Immune Monitoring Center, Mount Sinai
Professor, Immunology & Immunotherapy; Medicine, Hematology and Medical Oncology; Pathology, Molecular and Cell Based Medicine; Oncological Sciences

Seunghee Kim-Schulze, Ph.D.
Facility Director, Human Immune Monitoring Center, Mount Sinai
Associate Professor, Immunology and Immunotherapy

MD Anderson Cancer Center

Cara Haymaker, Ph.D.
Director, Oncology Research and Immuno-Monitoring (ORION) Core
Associate Professor, Department of Translational Molecular Pathology

Gheath Alatrash, M.D., Ph.D. 
Associate Professor, Department of Hematopoietic Biology and Malignancy

Stanford University

Holden Maecker, Ph.D.
Professor (Research), Microbiology and Immunology
Director, Human Immune Monitoring Center and Service Centers and Enabling Technologies

Sean Bendall, Ph.D.
Associate Professor, Pathology

Data Sharing through dbGaP and the NCI Cancer Research Data Commons (CRDC)

Clinical and biomarker data from CIMAC-CIDC correlative studies will be placed in the NCI Cancer Research Data Commons (CRDC) for sharing with the research community.
 
Those wishing to request data should submit their request to the database of Genotypes and Phenotypes (dbGaP).  If the request is approved, requesters would download the data from NCI’s Data Commons Framework Services (DCFS) portal.
 
Data available from CIMAC-CIDC studies are noted in the table of trials below, where the dbGaP webpage for each study is listed under its corresponding trial publication, along with the data’s dbGaP PHS number.

Steps to access the data

1. You must have a valid eRA Commons account.

  • To obtain an account, you must be affiliated with an organization that has already registered with eRA Commons. 
  • The eRA Commons Signing Official at your organization can create an account for you.  

2. Create a Login.gov account and link the two accounts.

3. Submit a Data Access Request (DAR) to dbGaP, which will be reviewed by the NCI Data Access Committee (DAC).

You may:

  • Submit one DAR for multiple studies.
  • Amend an existing DAR to include additional studies in the future, provided your proposed use of the data is consistent across studies. 
  • List multiple internal collaborators under a single DAR; however, collaborators external to your organization must submit their own DAR.

Steps for submitting a DAR to dbGaP

1. Log in to dbGaP Data Download portal using your eRA Commons account.

2. Navigate to “Authorized Access” > “My Projects” tab.

3. Select “Create New Project.”

4. Select “Begin New Research Project.”

5. Choose desired datasets on the "Projects Request" page.

  • Search PHS numbers in the "Study lookup" field in the "Filter Consents" panel.

6. Select “Add Selected and Continue” (bottom of page)

7. Complete forms in the following tabs (click “Save and Continue” after each tab):

  • Research Project
  • Cloud Providers
  • Collaborators
  • IT Director
  • Confirm Datasets
  • Review Data Use Certification (DUC). If NCI trial(s) included, also attach PDF showing you notified CTEP you intend to request the datasets. 
  • Review Data Use Limitations (DUL)

8. Select “Submit Application to Signing Official” on “Review Applications” tab.

9. Signing Official approves > NCI Data Access Committee (DAC) reviews and approves > CRADA collaborator(s) review (if NCI trial).

10. Check DAR status on “My Requests” tab; automatic emails notify you as DAR progresses through review steps.

Steps to download study data from NCI’s Data Commons Framework Services (DCFS) portal site after DAR approval

1. Log in to DCFS  using your eRA Commons account.

2. Select Profile (top right).

3. In Appendix I, click Distribution URL for desired study data to download. 

4. Return to browser tab used to log in to DCFS. 

5. A secure URL appears to download the data.

Standardized Assays

The CIMACs offer comprehensive profiling of specimens using standardized, validated assays.

The NCI Biospecimen Research Database contains the Standard Operating Procedures and analytical performance/validation reports for the CIMAC assays.

NIH reviewers review and approve all assays for validation and analytical performance.

Tissue-imaging Assays

  • Multiplex immunofluorescence
  • Multiplex immunohistochemistry
  • Singleplex immunohistochemistry (e.g., PD-L1)
  • Multiplexed Ion Beam Imaging (MIBI)
  • Spatial transcriptomics (Visium)
  • Spatial proteomics (GeoMx)
  • Spatial tissue imaging (CODEX)
  • MALDI-Glycan (Mass Spec)

Antigen prediction

  • Deconvolution of neoantigen-reactive TCRs
  • Immunopeptidomics

Soluble analyte assays

  • Olink cytokine analysis
  • ELISA Grand Serology
  • NULISA

Immune-cell profiling assays

  • Mass Cytometry (CyTOF)
  • ELISpot

Sequencing assays

  • RNA sequencing
  • Whole Exome Sequencing (WES)
  • NanoString
  • TCRseq
  • Assay for Transposase-Accessible Chromatin (ATAC-seq) 
  • Circulating free DNA (cfDNA)
  • 16S microbiome sequencing (stool)

Single-cell RNA sequencing

  • Single-nucleus RNA sequencing
  • Single-cell TCR sequencing
  • Single-cell ATAC-Seq
  • Single-cell RNA multi-omics sequencing (BD Rhapsody)
  • Extracellular vesicles and particles (EVP)
  • CITE-seq

Assay Harmonization

The network harmonized a core set of their assays to reduce data variability among assay sites to facilitate cross-trial analysis of correlative data:

Clinical Data Standardization and Specimens

Clinical Data Collections

CIDC collects clinical data that span the following range of information for CIMACs and trial teams to analyze with the assay data:

  • Demographics
  • Patient history
  • Disease characteristics
  • Treatment
  • Response
  • Adverse events

CIDC uses the following template and instructions to collect the clinical data:

Specimen standardization

In their “specimen collection umbrella,” CIMACs describe standardized specimen collections to support multi-assay specimen profiling:

Clinical Trial Collaborations and Publications

The CIMACs-CIDC Network collaborates with 42 clinical trials of immunotherapy in various cancer disease settings. 

Individual CIMACs and CIDC have published more than 230 additional manuscripts citing CIMAC-CIDC funding support. The pie chart below depicts the variety of clinical trials by cancer type, followed by a list of trials and biomarker publications for these trials. These publications offer insights into the mechanisms of tumor immunity and the methodologies for studying them.

The network’s Human Material Transfer Agreement (HMTA) describes the legal and regulatory terms governing collaborations with the CIMAC-CIDC Network.

Pie chart of number of clinical trials for a variety of cancer type that collaborate with the CIMAC-CIDC network, such as rare tumors, lung, pediatric, bladder, etc

Number of clinical trials by cancer type that are collaborating with the CIMACs-CIDC Network

Clinical trials collaborating with the CIMACs-CIDC Network and biomarker publications

Trial IDDescription
9204

A Phase I/IB Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

10013

Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)

10021

A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

10026

A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

10057A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
10061A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
10104

A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer

10166A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
10204A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
10208A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
10221A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors
10276A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
10300BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
10334BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
10347A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)
14-C-0059G

A Phase I Trial of T Cells Expressing an anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid Tumors

18-279 (NCT03929029)

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

2017-0349A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
21-066 (NCT04930783)A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab and in Patients With Melanoma
A151804Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
ABTC-1603

Phase I Study of Neoadjuvant GMCITM plus Immune Checkpoint Inhibitor Combined with Standard of Care for Newly Diagnosed High-Grade Gliomas

BACCIBACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab plus Atezolizumab versus Capecitabine Bevacizumab plus Placebo in Patients with Refractory Metastatic Colorectal Cancer
CA027-005A Phase 2a Multi-Cohort Trial of Neoadjuvant Nivolumab + BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL-8) for NSCLC or HCC
E4412

A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

EA6174A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
EAY131-Z1D

Molecular Analysis for Therapy Choice (MATCH) — MATCH Treatment Subprotocol Z1D: Phase 2 Study of Nivolumab in Patients with Mismatch Repair Deficiency

GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

LuTK02GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
NRG-GI002A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
NRG-GY021A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
NRG-LU004

Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

  • Clinical publication with CIMAC correlative findings: Lin SH, et al. (2026) Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With Durvalumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2026 Sep 12:S0360-3016(26)04286-0. doi: 10.1016/j.ijrobp.2026.08.075. 
OPTIMAL (TOP-1705)A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]
PED-CITN-02GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

  • Clinical publication with CIMAC correlative findings: Patel SP, Fisher J, Chae YK, et al. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort. Journal for ImmunoTherapy of Cancer 2025;13:e011760. doi:10.1136/jitc-2025-011760
S1400I

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

  • Updated:
Email